Palisade Bio (PALI) to Release Earnings on Tuesday

Palisade Bio (NASDAQ:PALI) is expected to be announcing its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($2.39) per share for the quarter.

Palisade Bio Stock Down 9.3 %

Shares of PALI stock opened at $0.71 on Monday. Palisade Bio has a 12 month low of $0.70 and a 12 month high of $9.65. The company’s fifty day simple moving average is $1.14 and its 200-day simple moving average is $2.19. The firm has a market cap of $1.97 million, a PE ratio of -0.05 and a beta of 1.49.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.